Preliminary Program: TUESDAY May 23
7 a.m.-8:30 a.m.
Industry-Supported Breakfast Symposia
IS26. Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths (Part 2)Supported by BristolMyers Squibb Co.
Bridging Pharmacology and Clinical Effectiveness in Schizophrenia Anissa Abi-Dargham, M.D. | |||||
Advances in Pharmacotherapy for Maintenance Treatment in Bipolar Disorder Terence A. Ketter, M.D. | |||||
IS27. Evidence, Outcomes, and Advocacy: Shaping the Management of GAD (Part 2)Supported by Cephalon Inc.
The Cognitive Expression of GAD David J. Nutt, M.D. | |||||
Gender Differences in GAD From Menarche to Menopause Marlene P. Freeman, M.D. | |||||
The Evidence Supporting Targeted Pharmacotherapy in GAD David V. Sheehan, M.D. | |||||
IS28. Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety (Part 2)Supported by Wyeth Pharmaceuticals
New Strategies to Address Anxiety and Resistant Somatic Symptoms Mark H. Rapaport, M.D. | |||||
How to Monitor Progress of Treatment of Depression With Anxiety Madhukar H. Trivedi, M.D. | |||||
7:30 a.m.-6 p.m.
Registration/Course Enrollment Open
8 a.m.-Noon
CME Courses 58-64
9 a.m.-10:30 a.m. Clinical Case Conferences
3. Rocking the Cradle: A Case of Postpartum InfanticideNicole F. Wolfe, M.D., Diana Dell, M.D., Alyson KuroskiMazzei, D.O., Donna M. Norris, M.D.(for APA members only) Continuous Clinical Case Conference 1.R. Rao Gogineni, M.D., Sheila Judge, M.D., Richard P. Kluft, M.D., Robert Michels, M.D., on 20 Therapies Later: Addressing Tranference Resistance (for APA members only)
Debate 2. Medications in Pregnancy and Lactation: What Have We Learned?Moderator: Linda L.M. Worley, M.D.
Discussion Groups
10. Eric Hollander, M.D., on New Developments in Impulse-Control Disorders and Autism
11. Vivien Burt, M.D., on TBD (Meet the Authors)
12. Robert Cabaj, M.D., on Gay Men and Crystal Meth Abuse
13. Carol Bernstein, M.D., on TBD
Lectures
L11. Personality Disorders: Psychiatry's Stepchildren Come of AgeJoel Paris, M.D. Distinguished Psychiatrist Lecture Series
L12. Prevention, Early Intervention, and EliminationLoretta E Duvall, APA's Patient Advocacy Award Lecture
L13. What Have We Learned About Alcoholism From Animal Models?Tiang Kai Li, M.D., Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Master Educator Clinical Consultations
7. Ronald O Rieder, M.D., on Building a Research Career in Psychiatry (for APA members only)
8. Michael Myers, M.D., on Treating Physicians and Their Families: Clinical Dilemmas (for APA members only)
9. Zebulon Taintor, M.D., on TBD (for APA members only)
Component Workshops
CW20. The End of Hospitalization? Trends in Intensive Mental Health Services for Children and AdolescentsAPA Council on Children, Adolescents, and Their Families; Co-Chairpersons: Brady G. Case, M.D., Harold Alan Pincus, M.D.
CW21. Bridge Suicide: The Prince Edward Viaduct in Toronto and the Golden Gate Bridge in San FranciscoAPA Northern California Psychiatric Society; Chairperson: Mel Blaustein, M.D.
CW22. You Can Be Leaders Too: A Workshop for IMGs and MinoritiesAPA Committee on International Medical Graduates; Chairperson: Josie L. Olympia, M.D.
CW23. Managed Pharmacy and Pay for Performance: The New Managed CareAPA Committee on Managed Care; Chairperson: Paul H. Wick, M.D.
CW24. Doing It in Public: Opportunities in Public Sector PsychiatryAPA Council on Social Issues and Public Psychiatry; Co-Chairpersons: Cassandra F. Newkirk, M.D., Matthew O. Hurford, M.D.
CW25. It Takes a Village: Assessing Behavioral and Psychiatric Disorders in Mentally Retarded IndividualsAPA Committee on Developmental Disabilities; Chairperson: Roxanne Dryden-Edwards, M.D.
CW26. Media Outreach to Latinos: Enhancing Access and Reducing StigmaAPA Committee of Hispanic Psychiatrists; Co-Chairpersons: Andres J. Pumariega, M.D., Ana E. Campo, M.D.
CW27. Buprenorphine: Clinical Issues and Managing More Complicated PatientsAPA Corresponding Committee on Training and Education in Addiction Psychiatry; Chairperson: John A. Renner Jr., M.D.
CW28. 10 Ways to Stay Out of Trouble: Ethics and EtiquetteAPA Ethics Committee and APA Ethics Appeal Board; Chairperson: Spencer Eth, M.D.
Issue Workshops
IW29. Pharmaceutical Bias in Presentations: Dos and Don'ts for EducatorsAssociation for Academic Psychiatry; Co-Chairpersons: Donald M. Hilty, M.D., Kelli J. R. Harding, M.D.
IW30. When Psychiatrists Get CancerChairperson: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.
IW31. The Creation and Function of a Mental Health CourtCo-Chairpersons: Lawrence K. Richards, M.D., Roger Peele, M.D.
IW32. Metabolic Screening of Patients on Antipsychotic Medications: Development of a Quality Improvement Program in an Urban Training Clinic;Co-Chairpersons: Diane B. Gottlieb, M.D., Karen Melendez, M.D.
IW33. The Difficult-to-Treat Bulimia NervosaChairperson: Jennifer L. McLain, M.D.
IW34. Initiating Couples Therapy TodayChairperson: Ian E. Alger, M.D.
IW35. Legal Issues in Consultation-Liaison PsychiatryChairperson: Renee M. Sorrentino, M.D.
IW36. Compulsive Hoarding: Conceptualization and TreatmentChairperson: Jose A. Yaryura-Tobias, M.D.
IW37. Cognitive Therapy for Personality DisordersChairperson: Judith S. Beck, Ph.D.
IW38. Evidence-Supported, RiskMinimizing, and Cost-Conscious Approaches in PsychopharmacologyChairperson: David N. Osser, M.D.
IW39. Murder Mysteries, Games, and Psychiatric Education: How and Why to Do a “Who Done It?”Chairperson: Andrea E. Waddell, M.D.
IW40. Practical Pharmacotherapy for the Treatment of Alcohol DependenceCollaborative Session With the National Institute on Alcohol Abuse and Alcoholism; Chairperson: Robert M. Swift, M.D.
IW41. How to Launch a Successful Private Practice: Part 1Co-Chairpersons: William E. Callahan Jr., M.D., Keith W. Young, M.D.
IW42. Grassroots Advocacy for Patients and for the Psychiatric Profession: How Medical Students, Residents, and Early Career Psychiatrists Can Affect the Legislative, Regulatory, and Political ProcessCo-Chairpersons: Jose P. Vito, M.D., Tony B. Shivers
9 a.m.-11 a.m.
Research Advances in Medicine Aging, Longevity, and Neurological DisordersChairperson: Anand Pandya, M.D.
9 a.m.-Noon
Media Workshop
MW3.“Crash”: A Portrait of Multicultural America at the FlashpointAPA Council on Minority Mental Health and Health Disparities; Co-Chairpersons: Francis G. Lu, M.D., Heather M. Hall, M.D.
9 a.m.-12:30 p.m.
Advances in Personality Disorders
John M. Oldham, M.D.
Continuous Clinical Case Conference
1.R. Rao Gogineni, M.D., Sheila Judge, M.D., Richard P. Kluft, M.D., Robert Michels, M.D., on 20 Therapies Later: Addressing Tranference Resistance (for APA members only)
9 a.m.-4 p.m.
CME Courses 65-70
10 a.m.-6 p.m.
Exhibits Open
APA Member Center Open Publishers' Bookfair Open
11 a.m.-12:30 p.m.
Discussion Groups
14. David McDowell, M.D., on The Clinical Use of Buprenorphine
15. Nada Stotland, M.D., on Emerging Issues in Women's Mental Health Care
16. Avram Mack, M.D., on Killer Adolescents: Drugs, School, and the Courts
17. Mary Jane Massie, M.D., on Psychotherapy With Women With Breast Cancer
18. TBD (for residents only.)
Lectures
L14. History of Mental Health Care Disparities and Corrective ProposalsMilton C. Hollar, M.D., APA's Solomon Carter Fuller Award Lecture
L15. Priorities, Initiatives, and Women's Health ResearchVivian Pinn, M.D.
L16. Psychiatric Implications of Displacement: The Emotional Costs of Losing Human HabitatMindy J. Fullilove, M.D. Distinguished Psychiatrist Lecture Series
Master Educator Clinical Consultations
10. Prakash S. Masand, M.D., on Atypical Antipsychotics: 2006 and Beyond (for APA members only)
11. John Livesley, M.D., on Current Issues in the Treatment of Personality Disorder (for APA members only)
12. Robin Hurley, M.D., on Neuropsychiatric Aspects of Traumatic Brain Injury (for APA members only)
Medical Update 2.Richard P. Brown, M.D., on ADD Kids Get Smart Naturally: Complementary Treatments for ADD
Research Consultation With 2.Paul S. Links, M.D., on Clinical Research Into Suicide
Scientific and Clinical Reports
Session 12. Gender Differences in Child and Adolescent Behaviors
34. Prediction of Suicidality and Violence in Hospitalized Adolescents: Comparisons by Gender Daniel F. Becker, M.D.
35. Daily Cigarette Smoking Among Colombian High School Students: Gender Related Factors Jorge A. MartínezMantilla
36. Subtypes of Aggression: Incidence and Gender Differences in Adolescents Melissa McMullin, B.A.
Session 13. Violence, Trauma, and Victimization
37. Terrorism: A Phenomenon at the Interface Between Individual and Group Psychology David A. Rothstein, M.D.
38. The Role of the Psychiatrist in Hospital Emergency Planning Julia B. Frank, M.D.
39. Psychopathological Effects of Workplace Harassment Jose L. Gonzalez de Rivera, M.D.
Session 14. Emotionality, Gender, and Life Satisfaction in Adolescents
40. The Role of Subjective Emotional Reactivity to Affective Pictures in Predicting Emotional-Behavior Disorders Over a One-Year Period in an Unselected Community Sample of Children Between the Ages of 7 and 11 Carla Sharp, Ph.D.
41. Life Satisfaction in Young Urban Adolescents Maribeth Pender, Ph.D.
42. Effectiveness of Group Interventions for Parents of Gender-Variant Children Edgardo J. Menvielle, M.D.
Session 15. Neurobiology and Psychoimmunology
43. Lymphocyte and Platelet Alteration of the 5HT Transporter in Patients With Psychosis Donatella Marazziti, M.D.
44. Potential Role of Interleukin-6 and HPA Axis in Breast Cancer Patients With MDD Haldun Soygur, M.D.
45. NMDA Receptors and BPD: A Critical Mediator Bernadette M. Grosjean, M.D.
Session 16. Medication Response in Bipolar Disorder
46. Galantamine-CR for Cognitive Dysfunction in Bipolar Disorder: Efficacy and Biological Correlates Dan V. Iosifescu, M.D.
47. Rate of Improvement With Quetiapine Across Different Symptoms and Symptom Clusters in Bipolar Disorder Terence A. Ketter, M.D.
48. Efficacy of the Antipsychotics in Anxiety Symptoms With or Without Bipolar Disorder Keming Gao, M.D.
Session 17. Prescription and Compliance in Bipolar Disorder
49. Prescription Patterns for Latin Americans Treated for MDD in Naturalistic Clinical Practice Settings Hector J. Duenas, M.D.
50. Nonadherence in Bipolar Disorder: A Qualitative Study Exploring Perceptual and Practical Barriers to Taking Medication Jane Clatworthy
51. Patient Dissatisfaction With Information Received About Medicines Prescribed for Bipolar Disorder Richard Bowskill
Session 18. Special Populations and Mood Disorders
52. Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic Distinction Giulio Perugi, M.D.
53. Treatment of SAD With a Carbohydrate-Rich Nutrient Mixture David Mischoulon, M.D.
54. Impaired Mood and Social Functioning Among Adult Children of Parents With Depression Christine Timko, Ph.D.
Session 19. Brain Imaging
55. fMRI of the Brain Reward System: Manipulation of Risk and Reward Value Juliana Yacubian, Ph.D.
56. Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort Erika Lauronen, M.D.
57. Progressive Glutamatergic and Gray Matter Changes in First-Episode Patients With Schizophrenia and High Field Proton MRS Peter C. Williamson, M.D.
Session 20. Medical Issues in the Treatment of Schizophrenia
58. Metabolic Syndrome in Thai Patients With Schizophrenia: Prevalence and Incidence Manit Srisurapanont, M.D.
59. The Swedish Study of Metabolic Risks in Psychiatry Urban P. Osby, M.D.
60. Olanzapine Treatment Does Not Increase 10-Year Cardiovascular Risk: Comparison With Haloperidol in Patients With Schizophrenia Yoram Barak, M.D.
Session 21. Neuropsychiatry
61. Psychosocial Treatment of Depression in Parkinson's Disease Amy Farabaugh, Ph.D.
62. Frequency of EEG Abnormalities and Results of Antiepileptic Drug Therapy in Unstable Mood Disorders Drake Duane, M.D.
63. Juvenile Epilepsy and Bipolar Disorder: Clinical Challenges Smadar Celestin-Westreich, Ph.D.
Session 22. International Epidemiology
64. Mental Health in Iranian Medical Students and Doctors Seyed M. Assadi, M.D.
65. Three-Year, Follow-Up Study of the Psychosocial Predictors of Delayed and Unresolved Post-Traumatic Stress Symptoms of Geriatric Earthquake Survivors in Yu-Chi, Taiwan Frank H. Chou, M.D.
66. Three-Year, Follow-Up Study of the Relationship Between Post-Traumatic Stress Symptoms and Quality of Life Among Geriatric Earthquake Survivors in Yu-Chi, Taiwan Kuan-Yi Tsai, M.D.
Component Workshops
CW29. Advances in the Treatment of Intimate Partner ViolenceAPA Rhode Island Psychiatric Society's Committee on Women; Chairperson: Alison M Heru, M.D.
CW30. Employment in the Post-Residency Years: Getting What You WantAPA Committee of Residents and Fellows; Chairperson: William C. Wood, M.D.
CW31. Can We Talk? A Model for Constructive Conversation Between Opponents and Advocates of SameSex RelationshipsAPA Corresponding Committee on Religion, Spirituality, and Psychiatry; Co-Chairpersons: John R. Peteet, M.D., Allan M. Josephson, M.D.
CW32. From Diagnosis to Treatment of Infants and Young ChildrenAPA Corresponding Committee on Infancy and Early Childhood; Chairperson: Irene Chatoor, M.D.
CW33. Moving the Psychiatric Agenda in the House of MedicineAPA/AMA Delegation Section Council on Psychiatry; Chairperson: Jack S. McIntyre, M.D.
CW34. European Psychiatry: Health and Mental Health Policy After the Helsinki SummitAPA Council on Global Psychiatry and the World Psychiatric Association Conflict Management and Conflict Resolution Section; Co-Chairpersons: Eliot Sorel, M.D., Rodrigo A. Muñoz, M.D.
CW35. From Fantasy to Reality: Recruitment of Minorities in Clinical ResearchAPA Council on Minority Mental Health and Health Disparities; Co-Chairpersons: Annelle B. Primm, M.D., Sanjay Dube, M.D.
CW36. Integrating Evidence-Based Psychiatry With Clinical IntelligenceAPA Lifers; Co-Chairpersons: Abram M. Hostetter, M.D., Sheila H. Gray, M.D.
Issue Workshops
IW43. The Psychiatry Resident as Educator: Implementation of a Teaching CurriculumCo-Chairpersons: Ruth M. Lamdan, M.D., Autumn Ning, M.D.
IW44. Teaching on the Fly: Practical Tips for Teaching Medical Students One-to-OneCo-Chairpersons: Andrea E. Waddell, M.D., Jodi S. Lofchy, M.D.
IW45. Infertility: From Patient Care to Advocacy and Public PolicyChairperson: Roxanne Dryden-Edwards, M.D.
IW46. An Integrative Approach to Cultural Competence Training for Resident and Staff PsychiatristsCo-Chairpersons: Kenneth P. Fung, M.D., Ted Lo, M.D.
IW47. Career Advancement in Academic Psychiatry for Early Career PsychiatristsCo-Chairpersons: Dimitri D Markov, M.D., Elisabeth J.S. Kunkel, M.D.
IW48. How to Launch a Successful Private Practice: Part 2Chairperson: William E. Callahan Jr., M.D.
IW49. Does Beauty Equal Happiness?Co-Chairpersons: Stephanie M. Stewart, M.D., Alicia R. Ruelaz, M.D.
IW50. Teaching Boundaries to Practicing CliniciansChairperson: Werner Tschan, M.D.
IW51. Multidisciplinary Treatment of Chronic PainCo-Chairpersons: Vladimir Bokarius, M.D., Steven H. Richeimer, M.D.
IW52. Are There Limits to Boundary Limits?Chairperson: Malkah T. Notman, M.D.
IW53. Sexual History: The Art and the ScienceCo-Chairpersons: Shahrad R. Amiri, M.D., Danni Z. Michaeli, M.D.
IW54. The Psychiatry Resident as Advocate: Practical Steps From the Clinic to the CapitolCo-Chairpersons: Joan M. Anzia, M.D., James L. Griffith, M.D.
Noon-1:30 p.m.
Forums
6. To Understand and Assess the Complex Issues of Addiction to Prescription MedicationNational Institute on Drug Abuse; Chairperson: Nora Volkow, M.D.
7. Hot Topics in Psychiatric Drug SafetyAPA Scientific Program Committee and APA Council on Research; Chairperson: P. Murali Doraiswamy, M.D.
8. Worldwide Interpersonal and Group Terrorism Toward WomenChairperson: Leah Dickstein, M.D.
9. Alcohol Related Research by Psychiatry ResidentsCollaborative Session With the National Institute on Alcohol Abuse and Alcoholism; Chairperson: Mark Willenbring, M.D.
Noon-2 p.m.
New Research Poster Session 6
1 p.m.-5 p.m.
CME Courses 71-78
2 p.m.-3:30 p.m.
Lectures
L17. Changing the Landscape of American Psychiatry: An AfricanAmerican Perspective on Feminine Expansive PersonalityAltha J. Stewart, M.D., APA's Alexandra Symonds Award Lecture
L18. Pharmacogenetics of Alcohol: Are We There Yet?Henry R. Kranzler, M.D., Frontiers of Science Lecture Series; Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
L19. An Evidence-Based Clinician's Guide to the New Pharmacotherapies for AlcoholismBarbara J. Mason, Ph.D., Frontiers of Science Lecture Series
2 p.m.-5 p.m.
Presidential Symposium 2. International Advocacy Toward a Psychiatry for the PersonWorld Psychiatric Association; Chairperson: Steven S. Sharfstein, M.D.
Symposia
S34. Predictors of Outcome and Treatment Response in Eating Disorders: Results From New Research on Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder
Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa B. Timothy Walsh, M.D. | |||||
Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa: Predictors of Outcome After One Year of Treatment Allan S. Kaplan, M.D. | |||||
Fluoxetine Versus Placebo to Prevent Relapse in Anorexia Nervosa: Body Composition Predicts Outcome After One Year of Treatment Laurel Mayer, M.D. | |||||
Early Response to Medication Among Women With Bulimia Nervosa Robyn Sysko, M.S. | |||||
Long-Term Outcome of Psychotherapy and Medication for BingeEating Disorder Michael J. Devlin, M.D. | |||||
S35. Impulsivity in Axis I and Axis II: Common Substrates, Different Presentations?
Compulsive Shopping: Epidemiology, Comorbidity, and Treatment Donald W. Black, M.D. | |||||
Pathological Gambling: From Neurobioloby to Evidence-Based Treatment Carlos Blanco-Jerez, M.D. | |||||
Borderline Personality Disorder: Affective or Impulse Control Disorder? S. Charles Schulz, M.D. | |||||
Kleptomania: Clinical Presentation, Neuroimaging, and Treatment Jon E. Grant, M.D. | |||||
S36. Diagnostic Criteria in Alzheimer's Disease and Dementia: Future Challenges
Neuroimaging as a Surrogate Marker of Dementia Gary W. Small, M.D. | |||||
Neuropsychological Testing in the Diagnosis of Dementia Mary Sano, Ph.D. | |||||
The Search for Biomarkers as Diagnostic Aides in Alzheimer's Disease Trey Sunderland, M.D. | |||||
S37. Bullying in the Workplace: Psychiatric and Public Health Perspectives
Setting the Stage: Prevalence, Antecedents, and Effects of Workplace Bullying Loraleigh Keashly, Ph.D. | |||||
Bullying at Work: Psychiatric Issues Renato Gilioli, M.D. | |||||
Workplace Bullying, Alcohol Use, Abuse, and Service Utilization Judith A. Richman, Ph.D. | |||||
Workplace Bullying and Employee Benefits: Enabling the Traumatized Worker to Seek Help for Psychiatric Illness David Yamada, J.D. | |||||
Syndrome of Morbidity Associated With School Bullying: Implications for Adulthood Jorge C. Srabstein, M.D. | |||||
S38. Screening, Diagnosis, and Management of Alcohol Use Disorders in Psychiatric PracticeCollaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Screening, Assessment, and Management Using the NIAAA Clinicians Guide Mark L. Willenbring, M.D. | |||||
Motivational Enhancement Strategies to Address Substance Use Disorders Douglas M. Ziedonis, M.D. | |||||
Integrating Pharmacotherapy for Alcohol Dependence Into General Psychiatric Practice Hugh Myrick, M.D. | |||||
Meeting the Addiction Medicine Needs of Patients in a General Psychiatric Practice Michael M. Miller, M.D. | |||||
S39. Therapeutic Neuromodulation: Methods and Mechanisms
Therapeutic Neuromodulation: The Arrival of a Paradigm Shift Mark Demitrack, M.D. | |||||
Vagus Nerve Stimulation: A Review of the Evidence Philip G. Janicak, M.D. | |||||
Repetitive Transcranial Magnetic Stimulation at 10 Hz in the Treatment of Pharmacoresistant Major Depression: Results From a Controlled Multicenter Clinical Trial John P. O'Reardon, M.D. | |||||
Therapeutic Neuromodulation Mechanisms of Action Elliott Richelson, M.D. | |||||
S40. APA Research Agenda forDSM-VPersonality Disorders
Alternative Dimensional Models: Toward an Integration Thomas A. Widiger, Ph.D. | |||||
Issues and Challenges in Developing an Etiologically Based Dimensional Classification of Personality Disorder Kerry L. Jang, Ph.D. | |||||
Toward A Developmental View of Personality Pathology Rebecca L. Shiner, Ph.D. | |||||
The Major Dimensions of Personality: Cross-Cultural Evidence Based on the Lexical Approach Michael C. Ashton, Ph.D. | |||||
Clinical Application of a Dimensional Model of Personality Disorder John Livesley | |||||
S41. Sleep, Fatigue, and Depression in Medically Ill Patients
Sleep and Fatigue in Breast Cancer Sonia Ancoli-Israel, Ph.D. | |||||
Sleep, Fatigue, Pain, and Depression in Patients With Diabetes Mellitus Wayne J. Katon, M.D. | |||||
Insomnia, Depression, Quality of Life, and Survival in Patients With EndStage Renal Disease and Following Renal Transplantation Marta Novak, M.D. | |||||
Sleep Disruption, Fatigue, and Depression in the Medically Ill Colin M. Shapiro, Ph.D. | |||||
S42. Scaling Up Against HIV/AIDS: A Culturally Sensitive and Comprehensive Approach
Understanding the Linkages Between HIV/AIDS and Development Scholastica Kimaryo | |||||
Culture, Indigenous Knowledge, and Information and Communications Technology in the Response to the HIV/AIDS Challenge Joseph Okpaku, M.D. | |||||
Defining and Describing a Modern Epidemic: The Case of HIV/AIDS in Sub-Sahara Africa Samuel O. Okpaku, M.D. | |||||
Challenges to Implement Culturally Adapted HIV/AIDS Programs in Haiti Vladimir Berthaud | |||||
S43. Suicide Research in Canada
Neurobiological Studies of Suicide Completers Gustavo Turecki, Ph.D. | |||||
Prospective Community Study of Suicidality in Young Adults Joel F. Paris, M.D. | |||||
Affective Instability and Suicidality in Borderline Personality Disorder Paul S. Links, M.D. | |||||
Clinical Guidelines for Suicidality Isaac Sakinofsky, M.D. | |||||
S44. Neurobiological Basis for Co-Occurring Substance Abuse and Other Psychiatric DisordersNational Institute on Drug Abuse
Smoking and Schizophrenia: Does Comorbidity of Substance Abuse and Disease Suggest Self-Medication? Sherry Leonard, Ph.D. | |||||
Insights From Animal Models of Dual Diagnosis: How Common Neurocircuit Abnormalities Underlie Both Mental Illness and Addiction Vulnerability Robert A. Chambers, M.D. | |||||
Nicotine-Induced Sensitization and ADHD Jean King, Ph.D. | |||||
Effects of Nicotine and Other Drugs of Abuse on Cognitive Dysfunction in Individuals With Schizophrenia Tony P. George, M.D. | |||||
S45. Bipolar Disorder and the U.S. Legal System
Bipolar Disorder and the Legal System Mark A. Frye, M.D. | |||||
Clinical and Legal Characteristics of Inmates With Bipolar Disorder Cameron D. Quanbeck, M.D. | |||||
An Epidemiologic Perspective on Forensic History in Bipolar I Disorder Benjamin I. Goldstein, M.D. | |||||
Can Psychiatry Reduce the Criminalization of the Severely Mentally Ill? Elizabeth Walsh, M.D. | |||||
S46. APA/APAL: Addressing Psychiatric Patients' Needs in Latin AmericaAPA Council on Global Psychiatry
APA/APAL Addressing Psychiatric Patients' Needs in Latin America Angel Valmaggia, M.D. | |||||
Future Perspectives With Respect to APA/APAL Cesar M. Mejias, M.D. | |||||
Structure of Strategic Collaboration Between APA and APAL Edgard Belfort, M.D. | |||||
Improving Mental Health Care in Latin America: The Role of International Cooperation Jose M. Caldas de Almeida, Ph.D. | |||||
S47. Helping Returning Veterans: Veterans Affairs Community Collaborations
The Public Health Approach in Department of Defense/Veteran Affairs Outreach to Service Members/Veterans and Their Families Harold Kudler, M.D. | |||||
A Model for Interagency Collaborative Care of Stress Disorders Related to Military Deployment Miles McFall, Ph.D. | |||||
Collaborative Interventions Addressing Sexual Trauma in Female Veterans Post-Deployment Marian I. Butterfield, M.D. | |||||
The Ohio Cares Initiative Col. Terry C. Washam, L.I.S.W. | |||||
S48. Substance Use Disorders: Planning a Research Agenda forDSM-V Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Adolescents and Substance-Related Disorders: Research Agenda to Guide Decisions on DSM-V Thomas J. Crowley, M.D. | |||||
Methods for DSM-V Research Workgroups to Address Key Diagnostic Issues for Substance Use Disorders Linda B. Cottler, Ph.D. | |||||
Substance Use Disorder Comorbidity and DSM-V Deborah S. Hasin, Ph.D. | |||||
What Can Human Brain Imaging Tell Us About Addiction? Anna R. Childress, M.D. | |||||
S49. The Use of Atypical Antipsychotics in Elderly Patients With Dementia: What Next?
Use of Antipsychotics in Elderly Patients With Dementia: What's Next? Soo Borson, M.D. | |||||
Pharmacological Strategies for the Management of Behavior Disorders in Dementia Bruce G. Pollock, M.D. | |||||
Thinking Outside the Black Box: Risk Management for Using Atypical Antipsychotic Medications With the Elderly Patricia R. Recupero, M.D. | |||||
S50. Prevention of Common Mental Disorders: Is It Time to Start?
Cost-Effectiveness of Preventing Depression in Primary Care Patients: randomized Trial Filip E Smit M.S.C. | |||||
Prevention of New Cases of Mental Disorders: Problems and Solutions Prof. Pim Cuijpers | |||||
Prevention of Late-life Depression: Do We Know Where to Begin? Robert A. Schoevers, M.D. | |||||
S51. How to Launch a Successful Private Practice: Part 3
Personal Factors Leading to a Successful Private Practice William E. Callahan Jr., M.D. | |||||
Office Location and Design for Efficiency and Success Keith W. Young, M.D. | |||||
Streamlining Overhead and Managing Your Business in Private Practice Keith W. Young, M.D. | |||||
Marketing Your Unique Private Practice William E. Callahan Jr., M.D. | |||||
S52. Choosing the Right Treatment for Substance Abuse
Choosing the Right Treatment for Cocaine Dependence Adam M. Bisaga, M.D. | |||||
Treatment of Comorbid Conditions Frances R. Levin, M.D. | |||||
Marijuana and Club Drugs: Cutting-Edge Developments, New and Potential Treatments David M. McDowell, M.D. | |||||
Behavioral Treatments for Substance Dependence and Integrating Behavioral Therapy With Medication Edward V. Nunes, M.D. | |||||
Choosing the Right Treatment for Opioid Dependence Herbert D. Kleber, M.D. | |||||
S53. Stress-Induced and Fear Circuitry Disorders: Planning the Research Agenda forDSM-V
The Role of Cognition in StressInduced and Fear Circuitry Disorders Edna B. Foa, Ph.D. | |||||
Overlap and Distinctiveness Among Stress-Induced and Fear-Circuitry Disorders Abby Fyer, M.D. | |||||
Neurochemisry/Neuroendocrine Signals and Noise in Anxiety Disorders Rachel Yehuda, M.D. | |||||
Serotonin, the Hippocampus, and Emotional Behavior Rene Hen, M.D. | |||||
S54. The Methamphetamine Epidemic in the U.S. National Institute on Drug Abuse
Neurobiological Effects of Methamphetamine Abuse: Acute and Long Term Linda Chang, M.D. | |||||
Methamphetamine Use, Abuse, Dependence, and Treatment: Survey Findings, 2002-2004 James D. Colliver, Ph.D. | |||||
The Epidemiolgy of Methampetamine Use in NYC: Prevention and Intervention Implications Perry Halkitis | |||||
S55. Preventing Schizophrenia: Opportunities and Challenges
Reducing the Damage of the First Psychosis Onset Ingrid Melle, M.D. | |||||
Treatment of the Schizophrenia Prodrome: Update 2006 Scott Woods, M.D. | |||||
Predicting Schizophrenia: Early Risk Factors Barbara A. Cornblatt, Ph.D. | |||||
Psychological Interventions for Those at Ultra High Risk of Psychosis Jean Addington, Ph.D. | |||||
Prevention Research in Psychosis: Current State of the Art Thomas H. McGlashan, M.D. | |||||
S56. HIV Update for Psychiatric Care
APA Committee on AIDS
HIV Medical Update Milton L. Wainberg, M.D. | |||||
Hepatitis C and HIV Infection Antoine B. Douaihy, M.D. | |||||
Club Drugs and HIV Khakasa H. Wapenyi, M.D. | |||||
Body Image and HIV Marshall Forstein, M.D. | |||||
S57. Voting by Persons With Cognitive Impairment
Voting by Persons With Cognitive Impairment: Overview of the Issues Richard Bonnie, J.D. | |||||
Voting By Persons With Cognitive Impairments: The Legal Issues Pamela Karlan | |||||
Assessing Competence to Vote in a Cognitively Impaired Population Paul S. Appelbaum, M.D. | |||||
Respecting Rights and Preserving The Integrity of Elections: The Challenges of Voting in Long-Term-Care Facilities Jason Karlawish, M.D. | |||||
S58. Not Your Parents' EEG: Clinical Applications of Auditory and Visual Event-Related Potentials
Event-Related Potential Abnormalities in Schizophrenia Daniel C. Javitt, M.D. | |||||
Probing the Cognitive, Clinical, and Functional Impairments of Schizophrenia Patients With Mismatch Negativity Gregory A. Light, Ph.D. | |||||
Event-Related Potential P300 and Mismatch Negativity Abnormalities in Patients at Ultra-High Risk for Schizophrenia Daniel H. Mathalon, M.D. | |||||
Use of Auditory Event-Related Potentials and Other Quantitative Measures in an Evidence-Based, Person-Centered Psychosis Treatment Program Steven B. Schwarzkopf, M.D. | |||||
S59. Genetic Findings Related to Alcohol Dependence and Related ConditionsCollaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Genetic Susceptibility for Alcohol Dependence: Recent Findings Howard J. Edenberg, Ph.D. | |||||
At-Risk Families: A Multigenerational Study of Alcoholism Laura J. Bierut, M.D. | |||||
Further Characterization of the Risk Associated With GABA-A Receptor Genes Danielle M. Dick, Ph.D. | |||||
Neurophysiological Endophenotypes and the Risk for Alcohol Dependence and Related Disorders Bernice Porjesz, Ph.D. | |||||
Prediction of Alcohol Problems Using a Prospective Longitudinal Design Including Genotype John I. Nurnberger Jr., M.D. | |||||
S60. The Meanings of Medication: Issues in Patients' Compliance With Psychotropic DrugsAmerican Academy of Psychoanalysis and Dynamic Psychiatry
Medication Management: A Clinical Misnomer Leah Davidson, M.D. | |||||
Compliance as Accord, Not Submission Eve Leeman M.D. | |||||
Transferences to Medication and Implications for the Structure of the Ego Eric R. Marcus, M.D. | |||||
Poison or Cure: Meanings of Medication in Schizophrenia Paul J. Rosenfield, M.D. | |||||
The Meanings of Medication: Issues in Patients' Compliance With Psychotropic Drugs: Be Careful What You Wish for Jeffrey Rubin, M.D. | |||||
S61. Pharmacogenetics and Drug Abuse ResearchNational Institute on Drug Abuse
Allele Specific Gene Expression in Addiction Genes Wolfgang Sadee | |||||
Assaying Functional SNPs for Psychiatric Disease Robert K. Moyzis, M.D. | |||||
Pharmacogenetics and Smoking Cessation With Nicotine Replacement Therapy Caryn Lerman, Ph.D. | |||||
Pharmacogenetics of Smoking Cessation Using Non-Nicotine Replacement Therapies Huijun Z. Ring, Ph.D. | |||||
Pharmacogenetics of Alcohol Treatment David W. Oslin, M.D. | |||||
S62. Eating Disorders 2006: From Science to Practice
Altered Dopamine and Optimal Stimulus Response in Anorexia Nervosa Walter H. Kaye, M.D. | |||||
Gender Difference Comparisons of Eating Difference Comparisons of Eating and Other Psychiatric Disorders in Course of Illness Katherine A. Halmi, M.D. | |||||
Federal Advocacy for Eating Disorders David B. Herzog, M.D. | |||||
Night Eating Syndrome James E. Mitchell III, M.Ed. | |||||
The 2006 APA Practice Guidelines for Eating Disorders Joel Yager, M.D. | |||||
S63. Vascular Depression: Measurement and Treatment Issues of a Proposed Diagnostic Entity
Vascular Risk Factors, Frontolimbic Dysfunction, and Course of Geriatric Depression George S. Alexopoulos, M.D. | |||||
Treatment of Vascular Depression Including New Data on rTMS Robert G. Robinson, M.D. | |||||
Neuroimaging of Cerebrovascular Disease David C. Steffens, M.D. | |||||
Vascular Depression: A Distinct Diagnostic Entity? Joel R. Sneed, Ph.D. | |||||
S64. Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders
History and Ethics of Neurosurgery for Treatment-Refractory Psychiatric Disorders George E. Tesar, M.D. | |||||
Deep Brain Stimulation Surgery for Treatment of Intractable Psychiatric Disorders Ali R. Rezai, M.D. | |||||
DBS for OCD: Targeting and Clinical Results Benjamin D. Greenberg, M.D. | |||||
Deep-Brain Stimulation in Psychiatric Disorders: Surgical Candidates and Preliminary Results in Major Depression Donald A. Malone Jr., M.D. | |||||
S65. Complex Depression: The Interface Between Personality Disorders and Major Depression
The Neurobiology of the Links Between Personality Traits and Depression Glenda M. MacQueen, M.D. | |||||
Patient Personality as a Differential Predictor of Treatment Outcome to Psychotherapy Versus Pharmacotherapy R. Michael Bagby, Ph.D. | |||||
Managing Patients With Complex Depression Sidney H. Kennedy, M.D. | |||||
Key Psychotherapy Issues in Complex Depression: Patients With Major Depression and Personality Psychopathology Michael B. Rosenbluth, M.D. | |||||
2 p.m.-5:30 p.m.
Advances in Psychodynamic Psychotherapy: The State of the ArtGlen O. Gabbard, M.D.
3 p.m.-5 p.m.
New Research Poster Session 7
7 p.m.-10 p.m.
Industry-Supported Symposia
IS34. Management of Psychosis in the Elderly: The Science and the ArtSupported by Solvay Wyeth Pharmaceuticals
Management of Psychosis in the Elderly: The Science and the Art Carl Salzman, M.D. | |||||
Efficacy and Effectiveness of Antipsychotics for Dementia Lon S. Schneider, M.D. | |||||
Safety of Antipsychotics in Elderly Patients Dilip V. Jeste, M.D. | |||||
Novel Antipsychotic Strategies: Implications for Biology and Future Treatment P. Murali Doraiswamy, M.D. | |||||
Nonpharmacologic Interventions for Psychosis in the Elderly Warachal E. Faison, M.D. | |||||
IS35. Multiple and Complex Presentations of Bipolar DisorderSupported by Abbott Laboratories
Presentations of Bipolar Disorder in Children and Adolescents Kiki D. Chang, M.D. | |||||
The Impulsive-Aggression Symptom Domain in Personality Disorders Eric Hollander, M.D. | |||||
Bipolar II Disorder and Suicidal Behaviors William H. Coryell, M.D. | |||||
Predicting Maintenance Response From the Acute Episode Charles L. Bowden, M.D. | |||||
IS36. Treating the Early Stages of SchizophreniaSupported by AstraZeneca Pharmaceuticals
Genetic and Clinical Risk Factors for Schizophrenia: Predicting the Onset and Outcomes of the Illness and Treatment Response Dolores Malaspina, M.D. | |||||
Treatment of First Episode Schizophrenia: Tolerability and Adherence Delbert G. Robinson, M.D. | |||||
Pharmacologic Strategies for the Treatment of Prodromal Schizophrenia Daniel C. Javitt, M.D. | |||||
Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection Jeffrey A. Lieberman, M.D. | |||||
Evaluation of Prodromal Schizophrenia Cheryl Corcoran, M.D. | |||||
IS37. Advocating for Change Through Evidence-Based Medicine: A Focus on ADHDSupported by Cephalon Inc.
Neurocircuitry of ADHD James J. Hudziak, M.D. | |||||
Phenomenology and Diagnosis of ADHD Christopher J. Kratochvil, M.D. | |||||
The Impact of Sleep/Wake Disturbances in ADHD Judith Owens, M.D. | |||||
Evidence-Based Pharmacotherapy of ADHD Timothy E. Wilens, M.D. | |||||
Role of Family and Social Support Systems in the Management of ADHD Scott Kollins, Pharm.D. | |||||
IS38. The Maze of Mood and Anxiety in the Elderly Patient: A Case SeriesSupported by GlaxoSmithKline
The Impact of Medical Comorbidity on Mood and Anxiety Disorders in the Elderly Patient Prakash S. Masand, M.D. | |||||
Achieving a Better Understanding of the Neurobiology of Mood and Anxiety Disorders in the Elderly Eric J.Lenze, M.D. | |||||
An Evidence-Based Approach to the Acute Management of Mood and Anxiety Disorders in the Elderly Population Warren D. Taylor, M.D. | |||||
Deciphering the Maze of Mood and Anxiety Symptoms in the Elderly Patient Charles F. Reynolds III, M.D. ▪ | |||||
